The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Making Artificial Intelligence systems robustly perceive humans remains one of the most intricate challenges in computer ...

While America retains a gold standard for airline safety, there are stresses on the US air travel system that have been apparent in a series of near tragedies in recent years. Aviation experts have ...

Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

Reni-cel treatment involves an ex vivo use of gene-editing – where the technology is used to modify a patient's own cells outside the body – and is playing catch-up with Vertex and CRISPR ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.